At major cardiology conference, Wegovy’s the word

LONDON — When Europe’s largest cardiology conference opened here this past Friday, one of the first sessions centered entirely on a single drug.

It cut the risk of complications from a common form of heart failure, researchers reported. It helped improve the structure of the heart as well as its function. It even saved the lives of people with Covid-19 — a respiratory infection of all things.

“Now on to something entirely different,” Richard Pratley, a diabetes specialist at AdventHealth in Orlando, told the standing-room-only crowd as he introduced a trial of the drug in kidney disease. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In